Last edition
News about " potential therapies for psychiatric disorders"
Neurocrine Biosciences Inc and Takeda Pharmaceutical Company Limited announced a strategic collaboration to develop and commercialise compounds in Takeda's early-to-mid-stage psychiatry pipeline. Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programmes, including three clinical stage assets
Potential Therapies For Psychiatric Disorders | 18/06/2020 | By Darshana | 185
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members